NRSNW
NeuroSense Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$0.01
+4.76%Next report
Analyst consensus
- Next report date
- Dec 2, 2026
- EPS estimate
- -$0.79
- Revenue estimate
- $535.6K
Latest reported
- Last report date
- Sep 25, 2026
- EPS actual
- -$2.06
- EPS estimate
- -$3.90
- Revenue actual
- —
- Revenue estimate
- $267.8K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -34.5%
- Revenue beats (12Q)
- —
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Sep 25, 2026 | -$3.90 | -$2.06 | Beat 47.18% | — |
| Mar 31, 2026 | -$0.07 | -$0.23 | Miss -231.92% | — |
| Nov 26, 2025 | -$0.04 | -$0.04 | Beat 8.47% | — |
| Aug 1, 2025 | -$0.22 | -$0.14 | Beat 38.14% | — |
| May 28, 2025 | -$0.10 | -$0.11 | Miss -4.80% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Dec 2, 2026